Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

XmAb657

Bispecific antibody · developed by Xencor

Phase 1 Most advanced trial
XNCR Developer
1 Registered trials

What is XmAb657?

XmAb657 is an investigational bispecific antibody that engages CD19 on B cells and CD3 on T cells. It is studied in idiopathic inflammatory myopathies, systemic sclerosis and Sjögren's disease.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type
Bispecific antibody
Therapy area
Immunology, Musculoskeletal
Developer
Xencor, Inc. (XNCR)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT07284797 Phase 1 Healthy Recruiting XNCR

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

HealthyIdiopathic Inflammatory MyopathiesSjögren's DiseaseSystemic Sclerosis

More from Xencor

Follow XNCR, the company behind XmAb657

See XNCR's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

XNCR catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.